COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
HC Q study #44
Source   PDF   Share   Tweet
See all 143 studies
5/27
Inconc.
Late treatment study
Goldman et al., NEJM, doi:10.1056/NEJMoa2015301 (Peer Reviewed)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Study focused on remdesivir but with results for HC Q in the supplementary appendix, showing 9% death with HC Q versus 12% control, unadjusted relative risk uRR 0.78, p = 0.46.
death, ↓22.3%, p=0.46
Source   PDF   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.
Submit